



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Demo Report

Report Issued 04/27/2020 08:54
Last Report Issued 03/13/2020 12:38

88888
Clinical Example Report
Attn: Example Reports
200 Welsh Road
Horsham, PA 19044

Patient Name 8756B-POS
Patient ID 8756B-POS
Chain 20000433
Age Not Given DOB Not Given
Gender Not Given
Workorder 20000433
Received 03/13/2020 10:53

Sample ID 20000433-001
Matrix Blood
Patient Name 8756B-POS
Patient ID 8756B-POS
Container Type Clear vial

Collect Dt/Tm Not Given
Source Not Given

Approx Vol/Weight Not Given

Receipt Notes Not frozen as required

Table with 5 columns: Analysis and Comments, Result, Units, Reporting Limit, Notes

8756B Novel Psychoactive Substances (NPS)
Screen 1, Blood

Analysis by High Performance Liquid Chromatography/Time of Flight-Mass Spectrometry (LC/TOF-MS)

Table with 4 columns: Substance Name, Result, Units, Reporting Limit. Rows include 2-Furanylfentanyl, 3-Fluorophenmetrazine, 3-MeO-PCP, 4-ANPP, 4-MeO-PCP, 25B-NBOMe, 25C-NBOMe.

Results for sample 20000433-001 are continued on next page



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
 Phone: (215) 657-4900 Fax: (215) 657-2972
 e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Sample ID 20000433-001
Matrix Blood
Patient Name 8756B-POS
Patient ID 8756B-POS

Collect Dt/Tm Not Given
Source Not Given

Analysis and Comments	Result	Units	Reporting Limit	Notes
Synonym(s): 2C-C-NBOMe				
25H-NBOMe	None Detected	ng/mL	1.0	
Synonym(s): 2C-H-NBOMe				
25I-NBOMe	None Detected	ng/mL	1.0	
Synonym(s): 2C-I-NBOMe				
Acetyl Fentanyl	None Detected	ng/mL	0.50	
Acryl Fentanyl	None Detected	ng/mL	0.10	
Acryl fentanyl is known to have limited stability in blood which may be dependent upon pH, collection tube, and storage temperature. Negative results should be interpreted with caution.				
alpha-PVP	None Detected	ng/mL	2.0	
Synonym(s): alpha-Pyrrolidinovalerophenone; alpha-pyrrolidinopentiophenone				
Bromazepam	See Comment	ng/mL	10	
Comment:	Based on this screening result, confirmation testing was performed. Refer to the confirmation test result(s).			
Butylone	None Detected	ng/mL	10	
Butyrylfentanyl	None Detected	ng/mL	0.10	
Synonym(s): Butyrfentanyl				
BZP	None Detected	ng/mL	10	
Synonym(s): 1-Benzylpiperazine				
Carfentanil	None Detected	ng/mL	0.10	
Synonym(s): Wildnil®				
cis-3-Methylfentanyl	None Detected	ng/mL	0.10	
Clephedrone	None Detected	ng/mL	50	
Synonym(s): 4-CMC; 4-chloromethcathinone				
Clephedrone is known to have limited stability in blood which may be dependent upon pH, collection tube, and storage temperature. Negative results should be interpreted with caution.				
Clonazepam	None Detected	ng/mL	5.0	
Cyclopropylfentanyl	None Detected	ng/mL	0.50	
Delorazepam	None Detected	ng/mL	5.0	

Results for sample 20000433-001 are continued on next page



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
 Phone: (215) 657-4900 Fax: (215) 657-2972
 e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Sample ID 20000433-001
Matrix Blood
Patient Name 8756B-POS
Patient ID 8756B-POS

Collect Dt/Tm Not Given
Source Not Given

Analysis and Comments	Result	Units	Reporting Limit	Notes
Synonym(s): Chlordesmethylidiazepam; Cloxazolam metabolite				
Deschloroetizolam	None Detected	ng/mL	2.0	
Dibutylone	None Detected	ng/mL	10	
Synonym(s): bk-DMBDB				
Diclazepam	None Detected	ng/mL	20	
Ethylone	None Detected	ng/mL	10	
Etizolam	None Detected	ng/mL	10	
Flubromazepam	None Detected	ng/mL	20	
Flubromazolam	None Detected	ng/mL	5.0	
Isobutyrylfentanyl	None Detected	ng/mL	0.10	
MDPV	None Detected	ng/mL	10	
Synonym(s): Methylenedioxyprovalerone				
Meclonazepam	None Detected	ng/mL	5.0	
Mephedrone	None Detected	ng/mL	10	
Synonym(s): 4-methylmethcathinone				
Mephedrone is known to have limited stability in blood which may be dependent upon pH, collection tube, and storage temperature. Negative results should be interpreted with caution.				
meta-Methylmethoxyacetylfentanyl	None Detected	ng/mL	0.50	
Synonym(s): 3-Methylmethoxyacetylfentanyl				
Methoxetamine	None Detected	ng/mL	2.0	
Methoxyacetylfentanyl	None Detected	ng/mL	0.50	
Methoxphenidine	None Detected	ng/mL	5.0	
Synonym(s): MXP				
Methylone	None Detected	ng/mL	10	
Methylone is known to have limited stability in blood which may be dependent upon pH, collection tube, and storage temperature. Negative results should be interpreted with caution.				
Mitragynine	None Detected	ng/mL	10	
Synonym(s): Kratom				
MPHP	None Detected	ng/mL	10	

Results for sample 20000433-001 are continued on next page



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Sample ID 20000433-001
Matrix Blood
Patient Name 8756B-POS
Patient ID 8756B-POS

Collect Dt/Tm Not Given
Source Not Given

Table with 5 columns: Analysis and Comments, Result, Units, Reporting Limit, Notes. Rows include various substances like N-Ethyl Pentylone, ortho-Fluorofentanyl, para-Fluorobutyrylfentanyl, etc., with their respective results and limits.

Results for sample 20000433-001 are continued on next page



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Sample ID 20000433-001
Matrix Blood
Patient Name 8756B-POS
Patient ID 8756B-POS

Collect Dt/Tm Not Given
Source Not Given

Table with 5 columns: Analysis and Comments, Result, Units, Reporting Limit, Notes. Row 1: Valeryl Fentanyl, None Detected, ng/mL, 0.50

Sample receipt condition is inappropriate for test code: Not frozen as required

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.

52502B Designer Benzodiazepines Confirmation
1, Blood

Analysis by High Performance Liquid Chromatography/ Tandem Mass Spectrometry (LC-MS/MS)

Table row: Bromazepam, 50, ng/mL, 5.0

Bromazepam is a benzodiazepine drug that is used as a novel psychoactive substance. It is reported to have CNS depressant properties and shares anticonvulsant, muscle relaxant, hypnotic, anxiolytic and sedative effects with other benzodiazepines. It is not approved for use in the United States, but is available in some other countries.

Average peak plasma concentrations following a single 3 mg, 6 mg and 12 mg dose were reported to be 10 ng/mL at 8 hours, 83 ng/mL at 2 hours and 130 ng/mL at 1-4 hours after dosing, respectively. Chronic oral administration of 9 mg daily resulted in an steady-state plasma concentrations of 81-150 ng/mL (Average = 120 ng/mL). Reported half-lives are 12 - 27 hours.

The blood to serum/plasma ratio is not known.

Table row: Clonazolam, 50, ng/mL, 5.0

Clonazolam is a benzodiazepine that is used as a novel psychoactive substance. It is reported to have CNS depressant properties and shares anticonvulsant, muscle relaxant, hypnotic, anxiolytic and sedative effects with other benzodiazepines. It is not marketed for use as a pharmaceutical product in any country.

Table row: Flubromazepam, 50, ng/mL, 20

Results for sample 20000433-001 are continued on next page



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Sample ID 20000433-001
Matrix Blood
Patient Name 8756B-POS
Patient ID 8756B-POS

Collect Dt/Tm Not Given
Source Not Given

Table with 5 columns: Analysis and Comments, Result, Units, Reporting Limit, Notes. Contains detailed text for Etizolam and Flubromazolam, including their pharmacological properties and clinical data.

Results for sample 20000433-001 are continued on next page



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Sample ID 20000433-001
Matrix Blood
Patient Name 8756B-POS
Patient ID 8756B-POS

Collect Dt/Tm Not Given
Source Not Given

Table header with columns: Analysis and Comments, Result, Units, Reporting Limit, Notes

A serum specimen analyzed approximately 19 hours post-ingestion of a reported 3 mg dose had a Flubromazolam concentration of 59 ng/mL.

The blood to serum/plasma ratio is not known.

Substance(s) known to interfere with the identity and/or quantity of the reported result: Oxazepam.

Table row for Delorazepam: Result 50, Units ng/mL, Reporting Limit 5.0

Synonym(s): Chlordesmethyldiazepam; Cloxazolam metabolite

Delorazepam is a benzodiazepine drug that is used as a novel psychoactive substance. It is reported to have CNS depressant properties and shares anticonvulsant, muscle relaxant, hypnotic, anxiolytic and sedative effects with other benzodiazepines.

In addition, the pharmaceutical benzodiazepine Cloxazolam is rapidly metabolized to delorazepam.

Average peak plasma concentrations of delorazepam following a single 4 mg dose of Cloxazolam was reported to be 16 ng/mL at 2 hours and the half-life of delorazepam was reported to be 137 hours.

The blood to plasma ratio is not known.

Table row for Phenazepam: Result 50, Units ng/mL, Reporting Limit 20

Phenazepam is a benzodiazepine drug that is used as a novel psychoactive substance. It is reported to have CNS depressant properties and shares anticonvulsant, muscle relaxant, hypnotic, anxiolytic and sedative effects with other benzodiazepines.

Average peak plasma concentrations following a single 3 mg and 5 mg dose were reported to be 24 ng/mL and

Results for sample 20000433-001 are continued on next page



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Sample ID 20000433-001
Matrix Blood
Patient Name 8756B-POS
Patient ID 8756B-POS

Collect Dt/Tm Not Given
Source Not Given

Analysis and Comments	Result	Units	Reporting Limit	Notes
-----------------------	--------	-------	-----------------	-------

38 ng/mL at 4 hours after dosing, respectively.
The reported half-life is 60 hours.

The blood to serum/plasma ratio is not known.

Substance(s) known to interfere with the identity and/or quantity of the reported result: Nordiazepam.

Diclazepam	50	ng/mL	5.0	
------------	----	-------	-----	--

Diclazepam is a benzodiazepine that is used as a novel psychoactive substance. It is reported to have CNS depressant properties and shares anticonvulsant, muscle relaxant, hypnotic, anxiolytic and sedative effects with other benzodiazepines. It is not marketed for use as a pharmaceutical product in any country.

The peak serum concentration following a single 1 mg oral dose was reported to be approximately 3.4 ng/mL at 3 hours. Diclazepam is metabolized to the active compounds delorazepam (chlordesmethyldiazepam), lormetazepam and lorazepam. Diclazepam may be detected in serum for at least to 4 days after use. The reported half-life is 42 hours.

The blood to serum/plasma ratio is not known.

Sample receipt condition is inappropriate for test code: Not frozen as required

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.

52503B Designer Benzodiazepines Confirmation 2, Blood

Analysis by High Performance Liquid Chromatography/
Tandem Mass Spectrometry (LC-MS/MS)

Pyrazolam	50	ng/mL	5.0	
-----------	----	-------	-----	--

Pyrazolam is a benzodiazepine that is used as a novel psychoactive substance. It is reported to have CNS depressant properties and shares anticonvulsant, muscle relaxant, hypnotic, anxiolytic and sedative effects with other benzodiazepines. It is not marketed for use as a pharmaceutical product in any country.

The peak serum concentration following a single

Results for sample 20000433-001 are continued on next page



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Sample ID 20000433-001
Matrix Blood
Patient Name 8756B-POS
Patient ID 8756B-POS

Collect Dt/Tm Not Given
Source Not Given

Analysis and Comments	Result	Units	Reporting Limit	Notes
<p>1 mg oral dose was reported to be approximately 50 ng/mL at 3 hours. Pyrazolam may be detected in serum for at least 4 days after use. The reported half-life is 17 hours.</p> <p>The blood to serum/plasma ratio is not known.</p> <p>Substance(s) known to interfere with the identity and/or quantity of the reported result: Oxazepam.</p>				
<p>Meclonazepam</p> <p>Meclonazepam is a benzodiazepine that is used as a novel psychoactive substance. It is reported to have CNS depressant properties and shares anticonvulsant, muscle relaxant, hypnotic, anxiolytic and sedative effects with other benzodiazepines. It is not marketed for use as a pharmaceutical product in any country.</p> <p>Substance(s) known to interfere with the identity and/or quantity of the reported result: Oxazepam.</p>	50	ng/mL	5.0	
<p>Deschloroetizolam</p> <p>Deschloroetizolam is a benzodiazepine that is used as a novel psychoactive substance. It is reported to have CNS depressant properties and shares anticonvulsant, muscle relaxant, hypnotic, anxiolytic and sedative effects with other benzodiazepines. It is not marketed for use as a pharmaceutical product in any country.</p>	50	ng/mL	2.0	

Sample receipt condition is inappropriate for test code: Not frozen as required

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.